| Capecitabine as adjuvant treatment for stage III colon cancer C Twelves, A Wong, MP Nowacki, M Abt, H Burris III, A Carrato, J Cassidy, ... New England Journal of Medicine 352 (26), 2696-2704, 2005 | 1744 | 2005 |
| International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer MI Canto, F Harinck, RH Hruban, GJ Offerhaus, JW Poley, I Kamel, Y Nio, ... Gut 62 (3), 339-347, 2013 | 886 | 2013 |
| NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses M García-Closas, N Malats, D Silverman, M Dosemeci, M Kogevinas, ... The Lancet 366 (9486), 649-659, 2005 | 795 | 2005 |
| Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools CM Villanueva, KP Cantor, JO Grimalt, N Malats, D Silverman, A Tardon, ... American journal of epidemiology 165 (2), 148-156, 2007 | 752 | 2007 |
| HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for … AN Bartley, MK Washington, CB Ventura, N Ismaila, C Colasacco, ... American journal of clinical pathology 146 (6), 647-669, 2016 | 619 | 2016 |
| Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non–small-cell lung cancer F Cardenal, MP López-Cabrerizo, A Antón, V Alberola, B Massuti, ... Journal of Clinical Oncology 17 (1), 12-12, 1999 | 600 | 1999 |
| Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium M Goggins, KA Overbeek, R Brand, S Syngal, M Del Chiaro, DK Bartsch, ... Gut 69 (1), 7-17, 2020 | 581 | 2020 |
| A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci N Rothman, M Garcia-Closas, N Chatterjee, N Malats, X Wu, JD Figueroa, ... Nature genetics 42 (11), 978-984, 2010 | 531 | 2010 |
| Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage M Porta, X Fabregat, N Malats, L Guarner, A Carrato, A De Miguel, L Ruiz, ... Clinical and Translational Oncology 7, 189-197, 2005 | 424 | 2005 |
| Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas S Hernández, E López-Knowles, J Lloreta, M Kogevinas, A Amorós, ... Journal of Clinical Oncology 24 (22), 3664-3671, 2006 | 415 | 2006 |
| Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers H Vasen, I Ibrahim, CG Ponce, EP Slater, E Matthäi, A Carrato, J Earl, ... Journal of Clinical Oncology 34 (17), 2010-2019, 2016 | 372 | 2016 |
| Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases … B Nordlinger, E Van Cutsem, P Rougier, CH Köhne, M Ychou, A Sobrero, ... European journal of cancer 43 (14), 2037-2045, 2007 | 372 | 2007 |
| Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final … E Díaz-Rubio, J Tabernero, A Gómez-España, B Massutí, J Sastre, ... Journal of Clinical Oncology 25 (27), 4224-4230, 2007 | 366 | 2007 |
| Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy C Balbás-Martínez, A Sagrera, E Carrillo-de-Santa-Pau, J Earl, ... Nature genetics 45 (12), 1464-1469, 2013 | 333 | 2013 |
| Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome Y Allory, W Beukers, A Sagrera, M Flández, M Marqués, M Márquez, ... European urology 65 (2), 360-366, 2014 | 331 | 2014 |
| A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs A Carrato, A Falcone, M Ducreux, JW Valle, A Parnaby, K Djazouli, ... Journal of gastrointestinal cancer 46, 201-211, 2015 | 319 | 2015 |
| PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors E López-Knowles, S Hernández, N Malats, M Kogevinas, J Lloreta, ... Cancer research 66 (15), 7401-7404, 2006 | 294 | 2006 |
| Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case–control study LE Moore, RM Pfeiffer, C Poscablo, FX Real, M Kogevinas, D Silverman, ... The lancet oncology 9 (4), 359-366, 2008 | 292 | 2008 |
| Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III … V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ... Journal of clinical oncology 21 (17), 3207-3213, 2003 | 272 | 2003 |
| Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF … M Martin, A Villar, A Sole-Calvo, R Gonzalez, B Massuti, J Lizon, ... Annals of Oncology 14 (6), 833-842, 2003 | 264 | 2003 |
Manolis KogevinasBarcelona Institute for Global Health (ISGlobal), Barcelona, Spainبريد إلكتروني تم التحقق منه على isglobal.org
